Back

Clinical outcomes of implantable cardioverter defibrillators in heart failure: a comparative analysis between ischemic and non-ischemic cardiomyopathy patients

12 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 2 Implantable Cardioverter-Defibrillator (ICD) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ines Ferreira Neves

Centro Hospitalar Universitario de Lisboa Central, E.P.E., Lisboa (Portugal)

7 More presentations in this session

Presentation thumbnail
Exercise capacity and factors associated in patients with heart failure
Doctor L. Klompstra (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Beyond 3 Months: unraveling the prolonged Impact of optimized medical therapy on LVEF and ICD implantation in HFrEF Patients
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Heart failure etiology and ARNI + SGLT2i initiation may influence implantable cardioverter-defibrillator implantation timing
Doctor J. Quintal (Setubal, PT)
Abstract Slides Video
Presentation thumbnail
ICD prescription as primary prevention in DCM in NYHA class I: single center experience
Miss M. Santalo i Corcoy (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Temporal trends in ICD prescription as primary prevention in non ischemic cardiomyopathy: 10 year single center registry
Miss A. Crehuet (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 2

The Event

Event poster

Heart Failure 2024

12 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Are patients with non-ischemic cardiomyopathy less deserving of primary prevention device implantation?
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up
thumbnail
Congress Presentation
Implantable cardioverter defibrillators in heart failure with reduced ejection fraction: evaluating efficacy in the era of contemporary pharmacotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources